ATLANTA, GA--(Marketwire - June 10, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX) today announced that data from its 6,144-patient ARISE Phase 3 clinical study of AGI-1067 (succinobucol) were presented at the 68th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California. The ADA's annual Scientific Sessions meeting is the largest gathering of health care professionals involved in diabetes research and the delivery of diabetes care.
